Rx Innovation Benefit Is Strongest Argument For Patents, PTO Director Says
The message that new drugs would not exist without strong patent protections is gaining acceptance from the international intellectual property community, Patent & Trademark Office Acting Director Jon Dudas said Feb. 23
You may also be interested in...
Pfizer's image research shows that the public is more receptive to discussions focused on health care outcomes than on campaigns to defend drug pricing
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials